Cell and gene therapies are typically developed using cells grown in a small-scale format, such as a well plate or T-flask. To bring such therapies through the process development, clinical trial, and commercial manufacturing phases, it is necessary to produce a progressively larger number of cells.
Cell cultures can be scaled out by increasing the number of vessels, but this approach increases the processing time proportionally. For adherent cell cultures, the best solution is to scale up by increasing the cell growth surface area of each vessel, which offers reduced processing time per million cells.
This seminar will explore several technologies for the initial scale up of adherent cell cultures and review considerations for subsequent scale up.